GSK (GSK) announced it has started shipping doses of its trivalent seasonal influenza vaccines to U.S. healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the FDA. Both Flulaval and Fluarix will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma call volume above normal and directionally bullish
- GSK’s Promising Phase 2b Study on Atopic Dermatitis Treatment
- GSK’s Belimumab Study: A Potential Game-Changer for Systemic Sclerosis Treatment?
- Drugmakers criticize Trump drug price negotiation plan, Bloomberg reports
- Pharma cos criticize Trump’s drug price negotiation plan, Bloomberg Law reports